Form 4: Boundless Bio Director Jennifer Lew Granted 16,000 Stock Options

Boundless Bio, Inc. Director Jennifer Lew was granted 16,000 stock options with an exercise price of $1.03, aligning her interests with the company's long-term performance.

Summary

• Jennifer Lew, a Director of Boundless Bio, Inc. (BOLD), was granted 16,000 stock options.
• The stock options have an exercise price of $1.03 per share.
• The transaction date for this grant was June 23, 2025.
• The options will vest in substantially equal monthly installments over 12 months following June 23, 2025.
• An alternative vesting condition states that if the next annual meeting of stockholders occurs prior to June 23, 2026, any remaining unvested portion will vest on the date of such annual meeting.
• Vesting is contingent upon Ms. Lew's continued service on the issuer's board of directors through the vesting date.
• The expiration date for these stock options is June 22, 2035.
• Following this transaction, Jennifer Lew beneficially owns 16,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is generally a neutral to slightly positive development as it aligns director incentives with shareholder interests. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options to Director Jennifer Lew aligns her financial interests with the long-term performance and shareholder value creation of Boundless Bio, Inc.
• The vesting schedule encourages continued service and commitment from a key board member.

Risks

• The value of the stock options is subject to the future performance of Boundless Bio, Inc.'s common stock, and there is no guarantee that the stock price will exceed the exercise price of $1.03.
• The vesting of the options is contingent on the director's continued service, meaning the options could be forfeited if service ceases before full vesting.

Future Outlook

The stock options granted to Director Jennifer Lew are set to vest over the 12 months following June 23, 2025, or potentially earlier upon the next annual meeting of stockholders before June 23, 2026, subject to her continued service on the board.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to incentivize long-term commitment and align the interests of board members with those of shareholders. This practice is a standard component of non-employee director compensation packages.

Comparison to Industry Standards

• The grant of 16,000 stock options to a non-employee director is within the typical range for early-stage biotechnology companies like Boundless Bio, Inc., which often use equity compensation to attract and retain experienced board members.
• The exercise price of $1.03, likely the fair market value on the grant date, is standard practice for incentive stock options.
• The 12-month vesting schedule, with a potential acceleration upon an annual meeting, is a common structure designed to ensure continued board engagement while providing a relatively quick path to liquidity for the director.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to more focused governance decisions aimed at increasing stock price.
• Employees: No direct impact on employees, but reflects standard corporate compensation practices.

Next Steps

• The stock options will begin vesting in monthly installments starting June 23, 2025.
• Jennifer Lew's continued service on the board of directors is required for the options to vest.

Key Dates

Keywords

Boundless Bio, BOLD, Stock Option Grant, Director Compensation, SEC Form 4, Equity Compensation, Insider Transaction, Jennifer Lew